Top entities: Catheter Precision, Vivo, Cardionomix, David Jenkins, United States — Food and Drug Administration.

What category does this event fall under?

Tech — classified as patent issuance.

What is the sentiment of coverage?

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Catheter Precision received notification · Catheter Precision issued patent European Union · Catheter Precision issued patent

Is this event still developing?

This is an active story, last updated Jul 06, 2026. Coverage continues to evolve.

Tech patent issuance

Catheter Precision Secures Two Patents

Q: When did this event occur?

First reported Jul 06, 2026; last updated Jul 06, 2026.

Q: What is the market impact?

General. The issuance of two key patents for Catheter Precision's Vivo and Cardionomix technologies is expected to positively impact the company's stock price due to enhanced intellectual property protection and potential for market growth in cardiac electrophysiology and heart failure treatment.

Analysis based on 6 articles · First reported Jul 06, 2026 · Last updated Jul 06, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The issuance of two key patents for Catheter Precision's Vivo and Cardionomix technologies is expected to positively impact the company's stock price due to enhanced intellectual property protection and potential for market growth in cardiac electrophysiology and heart failure treatment. This development could attract investor attention to the medical device sector, particularly companies focused on innovative cardiac solutions.

Medical Devices Healthcare

Event Summary

Catheter Precision, a US-based medical device company, announced the issuance of two significant patents. One patent, for European coverage, is for its Vivo technology, which precisely localizes cardiac arrhythmia using internal electrocardiography signals. This technology aims to improve the treatment of Ventricular Tachycardia. The second patent is for its Cardionomix heart failure portfolio, covering systems and methods for denoising physiological signals during electrical neuromodulation, a therapy for Acute Decompensated Heart Failure. David Jenkins, CEO of Catheter Precision, highlighted the potential of these technologies in addressing unmet medical needs and expanding market opportunities in the cardiac electrophysiology and heart failure treatment fields.

Key Actions

100 Catheter Precision received notification

90 Catheter Precision issued patent European Union

90 Catheter Precision issued patent

Entities Involved

priv

Catheter Precision

Catheter Precision announced the issuance of two key patents for its Vivo and Cardionomix technologies, which is expected to enhance its market position and potential for growth in the cardiac electrophysiology and heart failure treatment markets.

Importance 100.0 Sentiment 70.0

priv

Vivo

Vivo, a technology owned by Catheter Precision, received a European patent for precise localization of cardiac arrhythmia, which is crucial for its non-invasive 3D imaging system for ventricular arrhythmias.

Importance 80.0 Sentiment 60.0

priv

Cardionomix

Cardionomix, a medical device company owned by Catheter Precision, received a patent for systems and methods for denoising physiological signals during electrical neuromodulation, enhancing its technology for treating acute decompensated heart failure.

Importance 80.0 Sentiment 60.0

per

David Jenkins

As CEO of Catheter Precision, David Jenkins provided commentary on the significance of the new patents for the company's growth strategy and market potential in ventricular procedures and heart failure treatment.

Importance 70.0 Sentiment 60.0

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration previously granted marketing clearance for Catheter Precision's Vivo technology, indicating its regulatory approval in the US.

Importance 20.0 Sentiment 0.0

alliance

European Union

A patent for Catheter Precision's Vivo technology was issued for European coverage, expanding the company's intellectual property protection in the European market.

Importance 20.0 Sentiment 0.0

Relationships

United States — Food and Drug Administration related ↔ European Union

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard